Barclays reiterated their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a report released on Tuesday morning, Marketbeat Ratings reports. Barclays currently has a GBX 2,000 ($25.13) target price on the stock.
Separately, Berenberg Bank reiterated a hold rating and issued a GBX 2,000 ($25.13) price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of GBX 2,068.75 ($25.99).
Check Out Our Latest Research Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Up 0.6 %
Hikma Pharmaceuticals Increases Dividend
The firm also recently announced a dividend, which was paid on Friday, May 3rd. Shareholders of record on Thursday, March 21st were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, March 21st. This represents a yield of 1.86%. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.25. Hikma Pharmaceuticals’s payout ratio is presently 8,382.35%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Recommended Stories
- Five stocks we like better than Hikma Pharmaceuticals
- What Are Growth Stocks and Investing in Them
- Garmin Navigates to New Highs Driven By Wearables Trend
- Roth IRA Calculator: Calculate Your Potential Returns
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Best Stocks Under $5.00
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.